Huddinge, Sweden

Fredrik Öberg

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 3.3

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2019-2025

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Fredrik Öberg: Innovator in Cancer Treatment

Introduction

Fredrik Öberg is a notable inventor based in Huddinge, Sweden. He has made significant contributions to the field of cancer treatment, holding a total of 3 patents. His work focuses on innovative therapies that aim to improve patient outcomes in oncology.

Latest Patents

Öberg's latest patents include groundbreaking inventions such as a cancer treatment utilizing (2,2-bishydroxymethyl) methylenecyclopropane nucleotides. This invention provides a compound formula aimed at enhancing therapeutic efficacy. Another significant patent involves a combination therapy for liver cancer, which integrates sorafenib or regorafenib with a phosphoramidate prodrug of troxacitabine. This combination shows promising utility in treating liver cancer and liver metastasis, demonstrating Öberg's commitment to advancing cancer therapies.

Career Highlights

Throughout his career, Fredrik Öberg has worked with prominent companies in the pharmaceutical industry, including Medivir Aktiebolag and Medivir AB. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to the advancement of cancer treatment.

Collaborations

Öberg has collaborated with notable professionals in his field, including Björn Klasson and Mark Albertella. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his work.

Conclusion

Fredrik Öberg's contributions to cancer treatment through his patents and collaborations highlight his role as an influential inventor in the medical field. His innovative approaches continue to pave the way for advancements in oncology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…